The recent disappointing sales of drug-coated devices for peripheral arterial disease look likely to become the norm.
Merck & Co faces two US FDA decisions in June, and neither is an obvious guarantee of success.
Expectations are low for a three-year update on the group’s haemophilia A gene therapy, and Biomarin’s rivals could capitalise on any slip-up.
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
The small-molecule oncology player zeroes in on its first commercial opportunity.
Savara Pharmaceuticals seeks to grab investor attention with upcoming pivotal data with an inhaled GM-CSF, Molgradex.
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
Six months after floating, Urovant is gearing up to release pivotal data on its most advanced overactive bladder project.